Consuming aspiring regularly might be helpful in reducing the risks of liver cancer. That is the conclusion the researchers at the Harvard Medical School based at Massachusetts General Hospital reached. The new study confirms previous ones that estimated aspirin might lower the risk of hepatocellular carcinoma (HCC) which is the second-leading cause of cancers in the world.
“Regular use of aspirin led to a significantly lower risk of developing HCC, compared to infrequent or no aspirin use, and we also found that the risk declined progressively with increasing aspirin dose and duration of use. Since regular aspirin use carries the risk of increased bleeding, the next step should be to study its impact in populations with an established liver disease, a group that is already at risk for primary liver cancer,” said Tracey Simon, a researcher at the Massachusetts General Hospital.
Daily Aspirin Use Might Lower The Risks of Liver Cancer
Even though HCC is rare, it is a highly lethal form of cancer that evolves faster than any other carcinoma. Also, cirrhosis, which might be triggered by Hepatitis B or C, excessive alcohol use, or non-alcoholic fatty liver disease, is the first risk factor for HCC.
According to the researchers, aspirin is ideal in blocking the production of inflammatory lipids that could eventually trigger liver diseases. While some previous studies already said that, the right aspirin dosages to tackle that had not been found.
The new study was carried out on the data of 170,000 participants, gathered by specialists since the 1980s. According to the research, two or more standard-dose aspirin tablets per week caused a 49% reduction in the risks of liver cancer, including HCC.
“The long duration of aspirin use could be necessary because primary liver cancer takes many years to grow. Aspirin may act at the earliest stages of cancer development, or even at precancerous stages, by delaying or preventing inflammation or liver fibrosis,” Tracey Simon explained.